SEMA3B

Across TCGA pan-cancer cohorts, SEMA3B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SEMA3B data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SEMA3B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SEMA3B expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

PDAC, LSCC, and GBM are the cancer types where SEMA3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.617	0.853	.002	47	view →
LSCC	DFS	Tertile	III,IV	0.870	0.283	.002	19	view →
GBM	OS	Tertile	All	0.336	0.593	.009	13	view →
LUAD	OS	Median	II,III,IV	0.329	0.913	.001	9	view →
CCRCC	DFS	Quartile	III,IV	0.583	0.952	.017	8	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.375	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SEMA3B–PDAC (DFS)

Open the PDAC breakdown →